| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Alamar Biosciences, Inc.
13D/A
ALMR · 010911105
|
6.1% |
7/7/2026
Event 7/5/2026
|
||||
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.1% | |||||
| Sands Capital Alternatives, LLC | 6.1% | |||||
| Sands Frank M. | 6.1% | |||||
| Schedule 13G · 3 securities · passive | ||||||
|
Inhibikase Therapeutics, Inc.
13G/A
IKT · 45719W205
|
9.3% |
8/13/2026
Event 6/30/2026
|
||||
| Sands Capital Life Sciences Pulse Fund II, L.P. | 9.3% | |||||
| Sands Capital Alternatives, LLC | 9.3% | |||||
| Sands Frank M. | 9.3% | |||||
|
Acrivon Therapeutics, Inc.
13G/A
ACRV · 004890109
|
5.3% |
8/13/2026
Event 6/30/2026
|
||||
| Sands Capital Life Sciences Pulse Fund II, L.P. | 5.3% | |||||
| Sands Capital Alternatives, LLC | 5.3% | |||||
| Sands Frank M. | 5.3% | |||||
|
Beta Bionics, Inc.
13G/A
BBNX · 08659B102
|
8.2% |
8/13/2025
Event 6/30/2025
|
||||
| Sands Capital Life Sciences Pulse Fund II. L.P. | 8.2% | |||||
| Sands Capital Alternatives, LLC | 8.2% | |||||
| Sands Frank M. | 8.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.